Část stěžejních látek této bakalářské práce je vzhledem ke konfiguraci na C8 nepřesně zobrazena. Níže je uveden seznam sloučenin společně se stranami, kde v tomto pochybením došlo. Přesná zobrazení společně s absolutními konfiguracemi viz **Schéma 25.**

- **34a**: str. 15, 23 – 24, 26 – 27
- **34b**, **34c**, **34d**: str. 15, 27
- **35a**: str. 17 – 18, 23, 25 – 29, 36
- **35b**, **35c**: str. 17, 37 – 38
- **35d**: str. 17 – 18, 38
- **56a**: str. 23 – 24, 35
- **57a**: str. 23, 25 – 27, 35
- **57b, 57c, 57d**: str. 27
- **I**: str. 19, 21 – 23, 28 – 29, 39
- **II**: str. 19, 21 – 22, 29, 40
- **III – IV**: str. 19, 22, 29, 40 – 42



Schéma 25 - Přehled zobrazení sloučenin se správně vyznačenou stereochemií.

Na základě zmínky v posudku oponenta byly dohledány a opraveny nedostatky v ^{1}H NMR spektrech následujících sloučenin.

(1*S*,2*S*,4*S*,5*R*)-2-((*S*)-Azido(6-methoxychinolin-4-yl)methyl)-5-vinylchinuklidin (57a)

^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.78 (d, *J* = 4.4 Hz, 1H), 8.07 (d, *J* = 9.2 Hz, 1H), 7.47 (d, *J* = 2.7 Hz, 1H), 7.43 (dd, *J* = 9.2, 2.7 Hz, 1H), 7.33 (d, *J* = 4.5 Hz, 1H), 5.76 (ddd, J_1 = 17.4, J_2 = 10.3, J_3 = 7.2 Hz, 1H), 5.04 – 4.96 (m, 3H), 3.97 (s, 3H), 3.32 (dd, J_1 = 14.1, J_2 = 10.1 Hz, 1H), 3.27 – 3.17 (m, 1H), 2.94 – 2.81 (m, 2H), 2.30 (br m, 1H), 1.70 (br s, 1H), 1.69 – 1.65 (m, 1H), 1.63 – 1.58 (m, 1H), 1.58 – 1.51 (m, 1H), 1.46 – 1.34 (m, 1H), 0.77 (ddt, J_1 = 13.8, J_2 = 7.6, J_3 = 1.9 Hz, 1H) ppm.

(*S*)-(6-Methoxychinolin-4-yl)((1*S*,2*S*,4*S*,5*R*)-5-vinylchinuklidin-2-yl)methanamin (35a)

^{1}H NMR (400 MHz, MeOD) δ = 8.70 (d, *J* = 4.7 Hz, 1H), 7.98 (d, *J* = 9.2 Hz, 1H), 7.68 (s, 1H), 7.62 (d, *J* = 4.7 Hz, 1H), 7.46 (dd, J_1 = 9.2, J_2 = 2.7 Hz, 1H), 5.90 (ddd, J_1 = 17.5, J_2 = 10.3, J_3 = 7.6 Hz, 1H), 5.10 – 4.97 (m, 2H), 4.76 (d, *J* = 10.1 Hz, 1H), 4.02 (s, 3H), 3.41 – 3.34 (m, 1H), 3.34 – 3.28 (m, 1H), 3.28 – 3.17 (m, 1H), 2.91 – 2.80 (m, 2H), 2.37 (s, 1H), 1.64 (dd, J_1 = 12.7, J_2 = 4.8 Hz, 3H), 1.55 – 1.42 (m, 1H), 0.75 (ddt, J_1 = 13.5, J_2 = 7.5 Hz, 1H) ppm.

(*S*)-(6-Methoxychinolin-4-yl)((1*S*,2*S*,4*S*,5*R*)-5-vinylchinuklidin-2-yl)methanamin (35a)

^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.73 (d, *J* = 4.5 Hz, 1H), 8.02 (d, *J* = 9.2 Hz, 1H), 7.70 – 7.57 (m, 1H), 7.44 (d, *J* = 3.8 Hz, 1H), 7.37 (dd, J_1 = 9.2, J_2 = 2.7 Hz, 1H), 5.79 (ddd, J_1 = 17.5, J_2 = 10.3, J_3 = 7.5 Hz, 1H), 5.03 – 4.92 (m, 2H), 4.59 (d, *J* = 9.4 Hz, 1H), 3.95 (s, 3H), 3.27 (dd, J_1 = 13.8, J_2 = 10.0 Hz, 1H), 3.23 – 3.15 (m, 1H), 3.14 – 3.03 (m, 1H), 2.85 – 2.74 (m, 2H), 2.30 (s, 2H), 1.64 – 1.59 (m, 1H), 1.59 – 1.51 (m, 2H), 1.48 – 1.36 (m, 1H), 0.76 (ddt, J_1 = 13.6, J_2 = 5.9 Hz, 1H) ppm.

(*R*)-(6-Methoxychinolin-4-yl)((1*S*,2*S*,4*S*,5*R*)-5-vinylchinuklidin-2-yl)methanamin (35b)

^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.73 (d, *J* = 4.5 Hz, 1H), 8.01 (d, *J* = 9.2 Hz, 1H), 7.60 (br s, 1H), 7.51 (br s, 1H), 7.36 (dd, J_1 = 9.2, J_2 = 2.7 Hz, 1H), 5.87 (ddd, J_1 = 17.1, J_2 = 10.6, J_3 = 6.5 Hz, 1H), 5.10 – 5.01 (m, 2H), 4.66 (d, *J* = 9.4 Hz, 1H), 3.95 (s, 3H), 3.07 – 2.88 (m, 5H), 2.26 (m, 2H), 2.08 (br s, 1H), 1.64 – 1.59 (m, 1H), 1.58 – 1.51 (m, 2H), 1.13 (dd, J_1 = 13.5, J_2 = 8.8 Hz, 1H), 0.99 – 0.89 (m, 1H) ppm.

(*S*)-Chinolin-4-yl((1*S*,2*S*,4*S*,5*R*)-5-vinylchinuklidin-2-yl)methanamin (35c)

^{1}H NMR (400 MHz, CDCl3) δ = 8.89 (d, *J* = 4.5 Hz, 1H), 8.34 (br s, 1H), 8.13 (dd, J_1 = 8.6, J_2 = 1.3 Hz, 1H), 7.71 (ddd, J_1 = 8.4, J_2 = 6.8, J_3 = 1.4 Hz, 1H), 7.58 (ddd, J_1 = 8.4, J_2 = 6.8, J_3 = 1.4 Hz, 1H), 7.52 (d, *J* = 4.5 Hz, 1H), 5.79 (ddd, J_1 = 17.5, J_2 = 10.3, J_3 = 7.4 Hz, 1H), 5.04 – 4.92 (m, 2H), 4.71

(d, J = 10.2 Hz, 1H), 3.32 – 3.18 (m, 2H), 3.16 – 3.05 (m, 1H), 2.88 – 2.76 (m, 2H), 2.47 (s, 2H), 2.33 – 2.25 (m, 1H), 1.65 – 1.52 (m, 3H), 1.47 – 1.37 (m, 1H), 0.75 (ddt, J_1 = 13.8, J_2 = 7.4, J_3 = 1.9 Hz, 1H) ppm.

(*R*)-Chinolin-4-yl((1*S*,2*S*,4*S*,5*R*)-5-vinylchinuklidin-2-yl)methanamin (35d)

^{1}H NMR (400 MHz, MeOD) δ = 8.86 (d, J = 4.7 Hz, 1H), 8.43 (d, J = 8.5 Hz, 1H), 8.11 – 8.06 (m, 1H), 7.84 – 7.79 (m, 1H), 7.73 – 7.68 (m, 2H), 5.89 (ddd, J_1 = 17.2, J_2 = 10.5, J_3 = 6.7 Hz, 1H), 5.15 – 5.06 (m, 2H), 4.91 – 4.88 (m, 1H), 3.14 – 2.99 (m, 5H), 2.35 – 2.23 (m, 1H), 1.62 – 1.51 (m, 3H), 1.10 – 1.02 (m, 1H), 1.00 – 0.93 (m, 1H) ppm.

Tert-butyl-2-benzoyl-2‘-oxo-3-fenylspiro[cyklopropan-1,3‘-indolin]-1‘-karboxylát (66)

^{1}H NMR (600 MHz, CDCl3) δ = 7.98 (d, J = 7.8 Hz, 2H), 7.81 (d, J = 8.2 Hz, 1H), 7.56 (t, J = 7.3 Hz, 1H), 7.45 (dd, J_1 = 8.2, J_2 = 7.0 Hz, 2H), 7.37 – 7.29 (m, 5H), 7.28 (d, J = 7.0 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 7.10 (td, J = 7.6 Hz, 1H), 4.34 (d, J = 8.6 Hz, 1H), 4.11 (d, J = 8.5 Hz, 1H), 1.61 (s, 9H) ppm.